Abstract A137: Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers
Hernandez G, Bilic S, Guan Y, So J, Bhattacharya S, Wang B, Kotturi M, Oyasu M, Desbois M, Cao Y, Humke E, Ahern S, Sinclair A, Ulahannan S, Subbiah V, Pelster M, Lorusso P, Falchook G, Wang J, Barve M, Grewal J, Chow W, Henry J, Cecchini M, Takimoto C, Leabman M. Abstract A137: Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers. Molecular Cancer Therapeutics 2023, 22: a137-a137. DOI: 10.1158/1535-7163.targ-23-a137.Peer-Reviewed Original ResearchCleaved caspase-3Single agentNewly diagnosed cancerIgM monoclonal antibodyPreclinical mouse tumor modelsIgM antibodiesCasp-3Monoclonal antibodiesInduce tumor cell apoptosisPopulation PK modelPopulation PK analysisDose-dependent increaseMouse tumor modelsTumor cell apoptosisTerminal half-lifeTreatment-related increasesDose-dependent efficacyCleaved caspase-3 levelsEffects of ADAADA titersTwo-compartment modelPharmacodynamic changesTargeted therapyEfficacious dosePK analysis